Table 3. Summary of AEs in the safety and MET subgroup populations.
*Grade 5 AEs were cerebrovascular accident, respiratory failure, and sepsis.
Abbreviations: AE, adverse event; IHC, immunohistochemistry; MET, mesenchymal‐epithelial transition; Onartuzumab, onartuzumab plus bevacizumab plus mFOLFOX‐6; Placebo, placebo plus bevacizumab plus mFOLFOX‐6.